In vivo demonstration of an antithrombin effect of abciximab

American Journal of Cardiology

Volumn 86, Issue 2, 2000, Pages 150-152

  Ambrose, John A ^a   Hawkey, Marian ^a   Badimon, Juan J ^a   Coppola, John ^a   Geagea, Jean Pierre ^a   Rentrop, K Peter ^a   Domiguez, Alvaro ^a   Duvvuri, Srinivas ^a   Elmquist, Thomas ^a   Arias, Jose ^a   Doss, Ramy ^a   Dangas, George ^a  

^a ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBIN; HEPARIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART INFARCTION; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTITHROMBINS; CLINICAL TRIALS; CORONARY DISEASE; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PROTHROMBIN; WHOLE BLOOD COAGULATION TIME;

EID: 0034125135     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00851-1     Document Type: Article

References (11)

1. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study. Lancet. 349:1997;1429-1435.
2. Effects of platelet GP IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing myocardial infarction undergoing coronary angioplasty. Circulation. 1997:1997;1445-1453.
3. Use of a monoclonal antibody directed against the platelet GP IIb/IIIa receptor in a high risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
4. Mann K.G. Hemostasis and Thrombosis. 3rd ed. 1994;184-199 JB Lippincott, Philadelphia, PA.
5. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol E.J. Effect of platelet GP IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy. Am J Cardiol. 75:1995;559-562.
6. Platelet GP IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
7. Ammar T., Scudder L.E., Coller B.S. In vitro effects of the platelet GP IIb/IIIa receptor antagonist abciximab on the activated clotting time. Circulation. 95:1997;614-617.
8. Moorehead M.T., Westergard J.C., Bull B.S. Platelet involvement in the activated clotting time of heparinized blood. Anesth Analg. 63:1984;394-398.
9. Dangas G., Badimon J.J., Coller B.S., Fallon J.T., Sharma S.K., Hayes R.M., Meraj P., Ambrose J.A., Marmur J.D. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol. 18:1998;1342-1349.
10. Dangas G., Marmur J.D., King T.E., DeLeon J., Sharma S.K., Vidhun R., Felman D., Stoynov M.Y., Badimon J.J., Ambrose J.A. Effects of platelet GP IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J. 138:1999;49-54.
11. Kerensky R.A., Azar G.J. Jr, Bertolet B. Venous activated clotting time after intra-arterial heparin effect of site of administration and timing of sampling. Cathet Cardiovasc Diagn. 37:1996;151-153.